Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
Frequently asked questions
What sector does Predilife (ALPRE) operate in?
Predilife belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Predilife (ALPRE) current stock price?
As of the latest data, Predilife stock price is €1.49, with a previous close of €1.49.
What is Predilife (ALPRE) current market capitalization?
Predilife market cap is approximately 5.87 million.
What is Predilife (ALPRE) Earnings Per Share (EPS)?
The trailing EPS is -€1.00, and the forward EPS is -€1.53.
Does Predilife (ALPRE) pay dividends?
No. Predilife does not pay a dividend.
What is Predilife (ALPRE) beta (volatility) score?
Predilife has a beta of 0.249, indicating lower volatility than the overall market.
